Who are Tenofovir Disoproxil, Lamuvidine and Dolutegravir's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Symtuza® (TAF/FTC/DRV/c), abacavir/lamivudine + raltegravir.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tenofovir-disoproxil-lamuvidine-and-dolutegravir.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Tenofovir Disoproxil, Lamuvidine and Dolutegravir — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tenofovir Disoproxil, Lamuvidine and Dolutegravir (Tenofovir Disoproxil, Lamuvidine and Dolutegravir) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI/INST. Area: Infectious Diseases.

phase 3 NRTI/INST HIV-1 reverse transcriptase, HIV-1 integrase Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Tenofovir Disoproxil, Lamuvidine and Dolutegravir (Tenofovir Disoproxil, Lamuvidine and Dolutegravir) — Africa Health Research Institute. Tenofovir Disoproxil is a nucleotide reverse transcriptase inhibitor, Lamivudine is a nucleoside reverse transcriptase inhibitor, and Dolutegravir is an integrase strand transfer inhibitor.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Tenofovir Disoproxil, Lamuvidine and Dolutegravir TARGET	Tenofovir Disoproxil, Lamuvidine and Dolutegravir	Africa Health Research Institute	phase 3	NRTI/INST	HIV-1 reverse transcriptase, HIV-1 integrase
Symtuza® (TAF/FTC/DRV/c)	Symtuza® (TAF/FTC/DRV/c)	Fundacion SEIMC-GESIDA	marketed	Antiretroviral combination (NRTI/INSTI class with protease inhibitor)	HIV reverse transcriptase, HIV protease, CYP3A4
abacavir/lamivudine + raltegravir	abacavir/lamivudine + raltegravir	University of Modena and Reggio Emilia	phase 3	NRTI/INSTI combination	Reverse transcriptase/Integrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI/INST class)

Africa Health Research Institute · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tenofovir Disoproxil, Lamuvidine and Dolutegravir — Competitive Intelligence Brief. https://druglandscape.com/ci/tenofovir-disoproxil-lamuvidine-and-dolutegravir. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab